NCT06645912Completed
Effect of High Protein ONS on Older Gastric Cancer Patients Receiving Neoadjuvant Chemotherapy
Effect of High Protein Nutritional Supplementation on Nutritional Status, Functional Capacity and Quality of Life in Older Patients With Gastric Cancer Receiving Neoadjuvant Chemotherapy
Source: ClinicalTrials.gov · Last updated 18 Oct 2024
Brief summary (registry, in English)
This interventional prospective randomized controlled study was conducted to compare the effects of high-protein oral nutritional supplement (ONS) and medical nutritional therapy to medical nutrition therapy alone on nutritional status, quality of life, and physical function capacity after neoadjuvant chemotherapy in patients aged 65 and over with newly diagnosed locally advanced gastric cancer.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 46 (actual)
- First submitted
- 12 Oct 2024
- Start date
- 1 Feb 2023
- Primary completion date
- 1 Feb 2024
- Lead sponsor
- Erzincan Binali Yildirim University Mengucek Gazi Training and Research Hospital
- Diseases
- Gastric and esophageal cancer
- NCT number
- NCT06645912
What you commit to
- Study type: Interventional
- Participants enrolled: 46
- From 1 Feb 2023 to the primary completion date, 1 Feb 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Severe comorbidities affecting survival within 3 months.
- Inability to comply with study procedures.
- Previous gastric surgery or chemotherapy.
- Metastatic dissease (Stage IV)
- Poor performance status (ECOG 3-4)
- Early satge (Stage I)
Who the study is looking for
- • Aged 65 years or older.
- Newly diagnosed histological confirmed locally advanced gastric cancer (Stage IIa to IIIa).
- Scheduled to receive Neoadjuvant chemotherapy.
- ECOG performance status of 0-2.
- Signed informed consent to participate
Age in the registry: 65 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Erzincan Binali Yıldırım Üniversitesi Mengücek Gazi Eğitim ve Araştırma. Hastanesi Coordinator of this site? Confirm its status | Erzincan | Turkey (Türkiye) | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.